Despite advances in medicine, cardiovascular disease remains a leading cause of morbidity and mortality within Australia.¹

Patients with known coronary artery disease (CAD) have a high residual risk of subsequent major adverse cardiovascular events (MACE) compared to the general population, even when they have reached contemporary lipid-lowering targets and are adherent to antithrombotic therapy.

The inflammatory axis is pivotal in the development of atherosclerosis and plaque rupture. Large prospective trials have demonstrated that colchicine provides further cardioprotection in patients established on standard guideline-directed antithrombotic therapy and lipid-lowering therapy.

In this context, colchicine presents as an ideal therapeutic option for achieving further cardioprotection.²